Table 1.
General clinical data at baseline.
| Group 1 | P* | Group 2 | P † | |||
|---|---|---|---|---|---|---|
| Group 1A | Group 1B | Group 2A | Group 2B | |||
| Males/females (n) | 29/32 | 56/66 | 0.40 | 13/10 | 24/22 | 0.73 |
| Age (years) | 7.29 ± 3.99 | 8.61 ± 3.08 | 0.14 | 10.50 ± 2.78 | 10.35 ± 2.73 | 0.84 |
| Disease duration (months) | 1.72 ± 2.43 | 1.77 ± 2.42 | 0.90 | 21.09 ± 5.54 | 21.00 ± 5.72 | 0.95 |
| Glycosylated hemoglobin level (%) | 8.03 ± 1.41 | 8.01 ± 1.92 | 0.93 | 8.39 ± 1.23 | 8.67 ± 1.44 | 0.44 |
| Abnormal glycemic control rate (%) | 18.0 | 22.1 | 0.52 | 30.4 | 45.7 | 0.23 |
| BMI (kg/m2) | 16.74 ± 2.26 | 16.57 ± 1.92 | 0.61 | 17.54 ± 1.97 | 17.12 ± 2.45 | 0.48 |
| Insulin dosage (U/kg/d) | 0.59 ± 0.36 | 0.39 ± 0.24 | <0.01 | 0.58 ± 0.27 | 0.66 ± 0.23 | 0.19 |
| Blood glucose monitoring ≥4 times/day (%) | 76.3 | 62 | 0.15 | 70 | 31.3 | 0.13 |
∗Group 1A versus group 1B; †group 2A versus group 2B.